Chimerix (NASDAQ:CMRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Separately, ValuEngine lowered Chimerix from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th.

Shares of Chimerix (NASDAQ:CMRX) traded up $0.04 during trading on Tuesday, reaching $4.88. The company had a trading volume of 282,916 shares, compared to its average volume of 297,467. Chimerix has a twelve month low of $4.17 and a twelve month high of $6.64. The company has a market cap of $228.10, a price-to-earnings ratio of -3.41 and a beta of 1.46.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The firm had revenue of $0.90 million during the quarter, compared to analyst estimates of $0.81 million. Chimerix had a negative return on equity of 26.00% and a negative net margin of 1,440.67%. research analysts forecast that Chimerix will post -1.6 EPS for the current year.

In other Chimerix news, insider Linda M. Richardson sold 19,833 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $4.47, for a total transaction of $88,653.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its stake in shares of Chimerix by 19.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,728,095 shares of the biopharmaceutical company’s stock worth $9,072,000 after buying an additional 279,845 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Chimerix by 112.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 200,891 shares of the biopharmaceutical company’s stock worth $1,055,000 after buying an additional 106,267 shares during the last quarter. Citadel Advisors LLC boosted its stake in shares of Chimerix by 131.8% in the 3rd quarter. Citadel Advisors LLC now owns 165,490 shares of the biopharmaceutical company’s stock worth $869,000 after buying an additional 94,108 shares during the last quarter. Granite Investment Partners LLC boosted its stake in shares of Chimerix by 36.6% in the 3rd quarter. Granite Investment Partners LLC now owns 108,947 shares of the biopharmaceutical company’s stock worth $572,000 after buying an additional 29,194 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Chimerix in the 3rd quarter worth approximately $428,000. Hedge funds and other institutional investors own 70.32% of the company’s stock.

WARNING: “Chimerix (CMRX) Cut to Sell at Zacks Investment Research” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/09/chimerix-cmrx-cut-to-sell-at-zacks-investment-research.html.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.